The genomic risk of somatic gene therapy

Seminars in Cancer Biology

Volumn 20, Issue 4, 2010, Pages 269-278

  Kustikova, Olga ^a   Brugman, Martijn ^a   Baum, Christopher ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hematopoiesis; Insertional mutagenesis; Lentivirus; Oncogene; Retrovirus; Transposon; Tumor

Indexed keywords

BETA GLUCURONIDASE; DIHYDROFOLATE REDUCTASE; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; NERVE GROWTH FACTOR RECEPTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

BIOINFORMATICS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL TYPE; CHRONIC GRANULOMATOUS DISEASE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INSERTION; GENE MUTATION; GENE VECTOR; GENETIC STABILITY; GENOTOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; NONHUMAN; REVIEW; RISK REDUCTION; SOMATIC CELL; SOMATIC GENE THERAPY;

ANIMALS; CLONE CELLS; COMPUTATIONAL BIOLOGY; DNA DAMAGE; GENE THERAPY; GENETIC DISEASES, INBORN; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; RISK FACTORS;

EID: 77956868387     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.06.003     Document Type: Review

References (145)

1. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317(5837):477.
2. Baum C., Dullmann J., Li Z., Fehse B., Meyer J., Williams D.A., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101:2099-2114.
3. Baum C., Kustikova O., Modlich U., Li Z., Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 2006, 17(3):253-263.
4. Fehse B., Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther 2008, 15(2):143-153.
5. Dunbar C.E. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies. Ann NY Acad Sci 2005, 1044:178-182.
6. Nienhuis A.W., Dunbar C.E., Sorrentino B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006, 13(6):1031-1049.
7. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12(4):401-409.
8. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., et al. Murine leukemia induced by retroviral gene marking. Science 2002, 296:497.
9. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
10. Woods N.B., Bottero V., Schmidt M., von Kalle C., Verma I.M. Gene therapy: therapeutic gene causing lymphoma. Nature 2006, 440:1123.
11. Zhang X., Beard B.C., Trobridge G.D., Wood B.L., Sale G.E., Sud R., et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 2008, 118(4):1502-1510.
12. Seggewiss R., Pittaluga S., Adler R.L., Guenaga F.J., Ferguson C., Pilz I.H., et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006, 107(10):3865-3867.
13. Kustikova O.S., Fehse B., Modlich U., Yang M., Düllmann J., Kamino K., et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308:1171-1174.
14. Calmels B., Ferguson C., Laukkanen M.O., Adler R., Faulhaber M., Kim H.J., et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005, 106(7):2530-2533.
15. Deichmann A., Hacein-Bey-Abina S., Schmidt M., Garrigue A., Brugman M.H., Hu J., et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007, 117(8):2225-2232.
16. Schwarzwaelder K., Howe S.J., Schmidt M., Brugman M.H., Deichmann A., Glimm H., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007, 117(8):2241-2249.
17. Themis M., Waddington S.N., Schmidt M., von Kalle C., Wang Y., Al-Allaf F., et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 2005, 12:763-771.
18. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118(9):3132-3142.
19. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(5954):818-823.
20. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360(5):447-458.
21. Bainbridge J.W.B., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008, 358(21):2231-2239.
22. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
23. Björgvinsdóttir H., Ding C., Pech N., Gifford M.A., Li L.L., Dinauer M.C. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 1997, 89(1):41-48.
24. Dinauer M.C., Li L.L., Björgvinsdóttir H., Ding C., Pech N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 1999, 94(3):914-922.
25. Sadat M.A., Pech N., Saulnier S., Leroy B.A., Hossle J.P., Grez M., et al. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker. Hum Gene Ther 2003, 14(7):651-666.
26. Sadat M.A., Dirscherl S., Sastry L., Dantzer J., Pech N., Griffin S., et al. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Ther 2009, 16(12):1452-1464.
27. Brenner S., Ryser M.F., Choi U., Whiting-Theobald N., Kuhlisch E., Linton G., et al. Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells. Mol Ther 2006, 14(2):202-211.
28. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
29. Schmidt M., Hacein-Bey-Abina S., Wissler M., Carlier F., Lim A., Prinz C., et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 2005, 105:2699-2706.
30. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364:2181-2187.
31. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118(9):3143-3150.
32. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002, 296:2410-2413.
33. Aiuti A., Cassani B., Andolfi G., Mirolo M., Biasco L., Recchia A., et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007, 117(8):2233-2240.
34. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
35. Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16(2):198-204.
36. Li Z., Beutel G., Rhein M., Meyer J., Koenecke C., Neumann T., et al. High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 2009, 113(9):2028-2037.
37. Modlich U., Schambach A., Brugman M.H., Wicke D.C., Knoess S., Li Z., et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008, 22(8):1519-1528.
38. Kuramoto K., Follman D., Hematti P., Sellers S., Laukkanen M.O., Seggewiss R., et al. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood 2004, 104(5):1273-1280.
39. Davé U.P., Akagi K., Tripathi R., Cleveland S.M., Thompson M.A., Yi M., et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 2009, 5(5):e1000491.
40. Pike-Overzet K., de Ridder D., Weerkamp F., Baert M.R.M., Verstegen M.M., Brugman M.H., et al. Gene therapy: is IL2RG oncogenic in T-cell development?. Nature 2006, 443(7109):E5.
41. Thrasher A.J., Gaspar H.B., Baum C., Modlich U., Schambach A., Candotti F., et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006, 443(7109):E5-E6. discussion E6-7.
42. Scobie L., Hector R.D., Grant L., Bell M., Nielsen A.A., Meikle S., et al. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther 2009, 17(6):1031-1038.
43. Ginn S.L., Liao S.H.Y., Dane A.P., Hu M., Hyman J., Finnie J.W., et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 2010, 18(5):965-976.
44. Wicke D.C., Meyer J., Buesche G., Heckl D., Kreipe H., Li Z., et al. Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. Mol Ther 2010, 18(2):343-352.
45. Quang C.T., Wessely O., Pironin M., Beug H., Ghysdael J. Cooperation of Spi-1/PU.1 with an activated erythropoietin receptor inhibits apoptosis and Epo-dependent differentiation in primary erythroblasts and induces their Kit ligand-dependent proliferation. EMBO J 1997, 16(18):5639-5653.
46. Modlich U., Kustikova O.S., Schmidt M., Rudolph C., Meyer J., Li Z., et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005, 105:4235-4246.
47. Montini E., Cesana D., Schmidt M., Sanvito F., Bartholomae C.C., Ranzani M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119(4):964-975.
48. Marshall H.M., Ronen K., Berry C., Llano M., Sutherland H., Saenz D., et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE 2007, 2(12):e1340.
49. Felice B., Cattoglio C., Cittaro D., Testa A., Miccio A., Ferrari G., et al. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS ONE 2009, 4(2):e4571.
50. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
51. Cattoglio C., Facchini G., Sartori D., Antonelli A., Miccio A., Cassani B., et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007, 110(6):1770-1778.
52. Lewinski M.K., Yamashita M., Emerman M., Ciuffi A., Marshall H., Crawford G., et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006, 2(6):e60.
53. Beard B.C., Dickerson D., Beebe K., Gooch C., Fletcher J., Okbinoglu T., et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 2007, 15(7):1356-1365.
54. Mitchell R.S., Beitzel B.F., Schroder A.R., Shinn P., Chen H., Berry C.C., et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004, 2:E234.
55. Yant S.R., Wu X., Huang Y., Garrison B., Burgess S.M., Kay M.A. High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 2005, 25(6):2085-2094.
56. Hu J., Renaud G., Gomes T.J., Golmes T., Ferris A., Hendrie P.C., et al. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol Ther 2008, 16(9):1617-1623.
57. Trobridge G.D., Miller D.G., Jacobs M.A., Allen J.M., Kiem H.P., Kaul R., et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006, 103(5):1498-1503.
58. Hematti P., Hong B.K., Ferguson C., Adler R., Hanawa H., Sellers S., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004, 2:e423.
59. Laufs S., Nagy K.Z., Giordano F.A., Hotz-Wagenblatt A., Zeller W.J., Fruehauf S. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 2004, 10:874-881.
60. Kustikova O.S., Geiger H., Li Z., Brugman M.H., Chambers S.M., Shaw C.A., et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark " stemness" pathways. Blood 2007, 109(5):1897-1907.
61. Laufs S., Guenechea G., Gonzalez-Murillo A., Zsuzsanna Nagy K., Luz Lozano M., del Val C., et al. Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 2006, 8(10):1197-1207.
62. Beard B.C., Keyser K.A., Trobridge G.D., Peterson L.J., Miller D.G., Jacobs M., et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther 2007, 18(5):423-434.
63. Wilson M.H., Coates C.J., George A.L. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007, 15(1):139-145.
64. Narezkina A., Taganov K.D., Litwin S., Stoyanova R., Hayashi J., Seeger C., et al. Genome-wide analyses of avian sarcoma virus integration sites. J Virol 2004, 78(21):11656-11663.
65. Miller D.G., Trobridge G.D., Petek L.M., Jacobs M.A., Kaul R., Russell D.W. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005, 79(17):11434-11442.
66. Kustikova O., Fehse B., Modlich U., Yang M., Dullmann J., Kamino K., et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308:1171-1174.
67. Calmels B., Ferguson C., Laukkanen M.O., Adler R., Faulhaber M., Kim H.J., et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005, 106:2530-2533.
68. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110:521-529.
69. Schmidt M., Zickler P., Hoffmann G., Haas S., Wissler M., Muessig A., et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 2002, 100(8):2737-2743.
70. Wang G.P., Ciuffi A., Leipzig J., Berry C.C., Bushman F.D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res 2007, 17(8):1186-1194.
71. Recchia A., Bonini C., Magnani Z., Urbinati F., Sartori D., Muraro S., et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006, 103:1457-1462.
72. Berry C., Hannenhalli S., Leipzig J., Bushman F.D. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2006, 2(11):e157.
73. Gabriel R., Eckenberg R., Paruzynski A., Bartholomae C.C., Nowrouzi A., Arens A., et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009, 15(12):1431-1436.
74. Kustikova O.S., Schiedlmeier B., Brugman M.H., Stahlhut M., Bartels S., Li Z., et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009, 17(9):1537-1547.
75. Cassani B., Montini E., Maruggi G., Ambrosi A., Mirolo M., Selleri S., et al. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 2009, 114(17):3546-3556.
76. Wang G.P., Garrigue A., Ciuffi A., Ronen K., Leipzig J., Berry C., et al. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 2008, 36(9):e49.
77. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006, 24:687-696.
78. Bokhoven M., Stephen S.L., Knight S., Gevers E.F., Robinson I.C., Takeuchi Y., et al. Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol 2009, 83(1):283-294.
79. Modlich U., Navarro S., Zychlinski D., Maetzig T., Knoess S., Brugman M.H., et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009, 17(11):1919-1928.
80. Zychlinski D., Schambach A., Modlich U., Maetzig T., Meyer J., Grassman E., et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008, 16(4):718-725.
81. Arumugam P.I., Higashimoto T., Urbinati F., Modlich U., Nestheide S., Xia P., et al. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol Ther 2009, 17(11):1929-1937.
82. Evans-Galea M.V., Wielgosz M.M., Hanawa H., Srivastava D.K., Nienhuis A.W. Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther 2007, 15(4):801-809.
83. Ramezani A., Hawley T.S., Hawley R.G. Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 2008, 26(12):3257-3266.
84. Li C.L., Xiong D., Stamatoyannopoulos G., Emery D.W. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther 2009, 17(4):716-724.
85. Desprat R., Bouhassira E.E. Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator. PLoS ONE 2009, 4(6):e5956.
86. Hargrove P.W., Kepes S., Hanawa H., Obenauer J.C., Pei D., Cheng C., et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 2008, 16(3):525-533.
87. Maruggi G., Porcellini S., Facchini G., Perna S.K., Cattoglio C., Sartori D., et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther 2009, 17(5):851-856.
88. Gonzalez-Murillo A., Lozano M.L., Montini E., Bueren J.A., Guenechea G. Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors. Blood 2008, 112(8):3138-3147.
89. Cornils K., Lange C., Schambach A., Brugman M.H., Nowak R., Lioznov M., et al. Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther 2008, 17(1):131-143.
90. Newrzela S., Cornils K., Li Z., Baum C., Brugman M.H., Hartmann M., et al. Resistance of mature T cells to oncogene transformation. Blood 2008, 112(6):2278-2286.
91. Ochman H., Gerber A.S., Hartl D.L. Genetic applications of an inverse polymerase chain reaction. Genetics 1988, 120(3):621-623.
92. Dunbar C.E., Young N.S. Gene marking and gene therapy directed at primary hematopoietic cells. Curr Opin Hematol 1996, 3(6):430-437.
93. Devon R.S., Porteous D.J., Brookes A.J. Splinkerettes-improved vectorettes for greater efficiency in PCR walking. Nucleic Acids Res 1995, 23(9):1644-1645.
94. Eggert H., Bergemann K., Saumweber H. Molecular screening for P-element insertions in a large genomic region of Drosophila melanogaster using polymerase chain reaction mediated by the vectorette. Genetics 1998, 149(3):1427-1434.
95. Tolar J., Osborn M., Bell S., McElmurry R., Xia L., Riddle M., et al. Real-time in vivo imaging of stem cells following transgenesis by transposition. Mol Ther 2005, 12(1):42-48.
96. Mueller P.R., Wold B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 1989, 246(4931):780-786.
97. Pfeifer G.P., Steigerwald S.D., Mueller P.R., Wold B., Riggs A.D. Genomic sequencing and methylation analysis by ligation mediated PCR. Science 1989, 246(4931):810-813.
98. Izsvák Z., Ivics Z. Two-stage ligation-mediated PCR enhances the detection of integrated transgenic DNA. BioTechniques 1993, 15(5):814-818.
99. Schmidt M., Hoffmann G., Wissler M., Lemke N., Mussig A., Glimm H., et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther 2001, 12:743-749.
100. Kustikova O.S., Modlich U., Fehse B. Retroviral insertion site analysis in dominant haematopoietic clones. Methods Mol Biol 2009, 506:373-390.
101. Schmidt M., Schwarzwaelder K., Bartholomae C., Zaoui K., Ball C., Pilz I., et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007, 4(12):1051-1057.
102. Bozorgmehr F., Laufs S., Sellers S.E., Roeder I., Zeller W.J., Zeller W.J., et al. No evidence of clonal dominance in primates up to 4 years following transplantation of multidrug resistance 1 retrovirally transduced long-term repopulating cells. Stem Cells 2007, 25(10):2610-2618.
103. Bleier S., Maier P., Allgayer H., Wenz F., Zeller W.J., Fruehauf S., et al. Multiple displacement amplification enables large-scale clonal analysis following retroviral gene therapy. J Virol 2008, 82(5):2448-2455.
104. Akagi K., Suzuki T., Stephens R.M., Jenkins N.A., Copeland N.G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004, 32:D523-D527.
105. Hamady M., Walker J.J., Harris J.K., Gold N.J., Knight R. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods 2008, 5(3):235-237.
106. Pule M.A., Rousseau A., Vera J., Heslop H.E., Brenner M.K., Vanin E.F. Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy 2008, 10(5):526-539.
107. Vilen H., Aalto J., Kassinen A., Paulin L., Savilahti H. A direct transposon insertion tool for modification and functional analysis of viral genomes. J Virol 2003, 77(1):123-134.
108. Nagy K.Z., Laufs S., Gentner B., Naundorf S., Kuehlcke K., Topaly J., et al. Clonal analysis of individual marrow-repopulating cells after experimental peripheral blood progenitor cell transplantation. Stem Cells 2004, 22(4):570-579.
109. Willenbrock H., Salomon J., Søkilde R., Barken K.B., Hansen T.N., Nielsen F.C., et al. Quantitative miRNA expression analysis: comparing microarrays with next-generation sequencing. RNA 2009, 15(11):2028-2034.
110. Justice M.J., Morse HC3, Jenkins N.A., Copeland N.G. Identification of Evi-3, a novel common site of retroviral integration in mouse AKXD B-cell lymphomas. J Virol 1994, 68(3):1293-1300.
111. Joosten M., Vankan-Berkhoudt Y., Tas M., Lunghi M., Jenniskens Y., Parganas E., et al. Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites. Oncogene 2002, 21:7247-7255.
112. Martín-Hernández J., Sørensen A.B., Pedersen F.S. Murine leukemia virus proviral insertions between the N-ras and unr genes in B-cell lymphoma DNA affect the expression of N-ras only. J Virol 2001, 75(23):11907-11912.
113. Lund A.H., Turner G., Trubetskoy A., Verhoeven E., Wientjens E., Hulsman D., et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 2002, 32:160-165.
114. Bijl J., Sauvageau M., Thompson A., Sauvageau G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev 2005, 19(2):224-233.
115. Hwang H.C., Martins C.P., Bronkhorst Y., Randel E., Berns A., Fero M., et al. Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci USA 2002, 99:11293-11298.
116. Castilla L.H., Perrat P., Martinez N.J., Landrette S.F., Keys R., Oikemus S., et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA 2004, 101(14):4924-4929.
117. Iwasaki M., Kuwata T., Yamazaki Y., Jenkins N.A., Copeland N.G., Osato M., et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. Blood 2005, 105(2):784-793.
118. Uren A.G., Mikkers H., Kool J., van der Weyden L., Lund A.H., Wilson C.H., et al. A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc 2009, 4(5):789-798.
119. Pike-Overzet K., de Ridder D., Weerkamp F., Baert M.R.M., Verstegen M.M.A., Brugman M.H., et al. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007, 21(4):754-763.
120. Suzuki T., Shen H., Akagi K., Morse H.C., Malley J.D., Naiman D.Q., et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002, 32:166-174.
121. Abel U., Deichmann A., Bartholomae C., Schwarzwaelder K., Glimm H., Howe S., et al. Real-time definition of non-randomness in the distribution of genomic events. PLoS ONE 2007, 2(6):e570.
122. de Ridder J., Uren A., Kool J., Reinders M., Wessels L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2006, 2:e166.
123. de Ridder J., Kool J., Uren A., Bot J., Wessels L., Reinders M. Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. Bioinformatics 2007, 23(13):i133-i141.
124. Wang G.P., Levine B.L., Binder G.K., Berry C.C., Malani N., McGarrity G., et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 2009, 17(5):844-850.
125. Kim S., Kim N., Dong B., Boren D., Lee S.A., Das Gupta J., et al. Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol 2008, 82(20):9964-9977.
126. Faschinger A., Rouault F., Sollner J., Lukas A., Salmons B., Günzburg W.H., et al. Mouse mammary tumor virus integration site selection in human and mouse genomes. J Virol 2008, 82(3):1360-1367.
127. Brady T., Lee Y.N., Ronen K., Malani N., Berry C.C., Bieniasz P.D., et al. Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev 2009, 23(5):633-642.
128. Brady T., Agosto L.M., Malani N., Berry C.C., O'Doherty U., Bushman F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009, 23(12):1461-1471.
129. Monse H., Laufs S., Kuate S., Zeller W.J., Fruehauf S., Uberla K. Viral determinants of integration site preferences of simian immunodeficiency virus-based vectors. J Virol 2006, 80(16):8145-8150.
130. Moalic Y., Félix H., Takeuchi Y., Jestin A., Blanchard Y. Genome areas with high gene density and CpG island neighborhood strongly attract porcine endogenous retrovirus for integration and favor the formation of hot spots. J Virol 2009, 83(4):1920-1929.
131. Meekings K.N., Leipzig J., Bushman F.D., Taylor G.P., Bangham C.R.M. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog 2008, 4(3):e1000027.
132. Hackett P.B., Largaespada D.A., Cooper L.J.N. A transposon and transposase system for human application. Mol Ther 2010, 18(4):674-683.
133. Coates C.J., Kaminski J.M., Summers J.B., Segal D.J., Miller A.D., Kolb A.F. Site-directed genome modification: derivatives of DNA-modifying enzymes as targeting tools. Trends Biotechnol 2005, 23(8):407-419.
134. Yant S.R., Huang Y., Akache B., Kay M.A. Site-directed transposon integration in human cells. Nucleic Acids Res 2007, 35(7):e50.
135. Ivics Z., Katzer A., Stuwe E.E., Fiedler D., Knespel S., Izsvak Z. Targeted Sleeping Beauty transposition in human cells. Mol Ther 2007, 15(6):1137-1144.
136. Mátés L., Chuah M.K.L., Belay E., Jerchow B., Manoj N., Acosta-Sanchez A., et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009, 41(6):753-761.
137. Chalberg T.W., Portlock J.L., Olivares E.C., Thyagarajan B., Kirby P.J., Hillman R.T., et al. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 2006, 357(1):28-48.
138. Liu J., Jeppesen I., Nielsen K., Jensen T.G. Phi c31 integrase induces chromosomal aberrations in primary human fibroblasts. Gene Ther 2006, 13(15):1188-1190.
139. Ehrhardt A., Yant S.R., Giering J.C., Xu H., Engler J.A., Kay M.A. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol Ther 2007, 15(1):146-156.
140. Bohne J., Cathomen T. Genotoxicity in gene therapy: an account of vector integration and designer nucleases. Curr Opin Mol Ther 2008, 10(3):214-223.
141. Grizot S., Smith J., Daboussi F., Prieto J., Redondo P., Merino N., et al. Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res 2009, 37(16):5405-5419.
142. Ambrosi A., Cattoglio C., Di Serio C. Retroviral integration process in the human genome: is it really non-random? A new statistical approach. PLoS Comput Biol 2008, 4(8):e1000144.
143. Kustikova O.S., Baum C., Fehse B. Retroviral integration site analysis in hematopoietic stem cells. Methods Mol Biol 2008, 430:255-267.
144. Peters B., Dirscherl S., Dantzer J., Nowacki J., Cross S., Li X., et al. Automated analysis of viral integration sites in gene therapy research using the SeqMap web resource. Gene Ther 2008, 15(18):1294-1298.
145. Appelt J., Giordano F.A., Ecker M., Roeder I., Grund N., Hotz-Wagenblatt A., et al. QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther 2009, 16(7):885-893.